iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Sun Pharma's Stock Surges 4% as Taro Pharma Reports Strong Q3 Performance

29 Jan 2024 , 03:40 PM

Sun Pharmaceutical Industries Limited’s shares surged 4% to reach a record high of ₹1,420.85 on the NSE following robust performance by its subsidiary Taro Pharmaceutical Industries in Q3FY24.

Taro reported a Q3 profit of $20.2 million, a significant increase from $7.3 million in the same quarter of the previous year. The company’s Q3 revenue rose by 13% YoY, reaching $157.14 million.

Taro Pharma’s operating income for the third quarter was $15.83 million, compared to $1.3 million in the corresponding quarter of the previous fiscal, with margins at 10.8%.

Sun Pharma is set to acquire the remaining 21.52% stake in Taro Pharmaceutical Industries for ₹2,891.7 crore this month, consolidating its control over Taro. Sun Pharma currently holds 78.48% of Taro.

The deal, marking the end of nearly 17 years of negotiations, follows Sun Pharma’s previous attempts to gain full control over the US-listed generic drugmaker, which operates mainly in the United States and Canada.

Upon completion of the merger, expected in the first half of the year, Taro will become a privately held company and be delisted from the New York Stock Exchange.

For feedback and suggestions, write to us at editorial@iifl.com
 

Related Tags

  • Q3 Performance
  • Sun Pharma
  • Taro Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.